Beat the Market the Zacks Way: Shopify, Lululemon, Telos in Focus
https://www.zacks.com/stock/news/2195999/beat-the-market-the-zacks-way-shopify-lululemon-telos-in-focus?cid=CS-ZC-FT-analyst_blog|investment_ideas-2195999
Dec 11, 2023 - Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
0
3 Medicare Gotchas That Could Cost You a Fortune
https://www.fool.com/retirement/2023/12/10/3-medicare-gotchas-that-could-cost-you-a-fortune/?source=iedfolrf0000001
Dec 10, 2023 - You might spend a lot more under Medicare than expected. Consider yourself warned,
0
Solid Balance Sheet Aids PNC Financial (PNC), High Costs Ail
https://www.zacks.com/stock/news/2195729/solid-balance-sheet-aids-pnc-financial-pnc-high-costs-ail?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2195729
Dec 08, 2023 - PNC Financials' (PNC) solid balance sheet and strategic initiatives will continue supporting its financials. However, a rise in costs will hurt.
0
Adobe (ADBE) to Post Q4 Earnings: What's in the Offing?
https://www.zacks.com/stock/news/2195710/adobe-adbe-to-post-q4-earnings-what-s-in-the-offing?cid=CS-ZC-FT-analyst_blog|earnings_preview-2195710
Dec 08, 2023 - Adobe's (ADBE) fiscal Q4 performance is likely to reflect strength across the Digital Media and Digital Experience businesses.
0
Effective Pricing Actions Aid B&G Foods (BGS) Amid High Costs
https://www.zacks.com/stock/news/2195639/effective-pricing-actions-aid-b-g-foods-bgs-amid-high-costs?cid=CS-ZC-FT-analyst_blog|rank_focused-2195639
Dec 08, 2023 - B&G Foods (BGS) is reaping benefits from continued margin recovery on the back of pricing actions undertaken to counter inflationary costs through pricing and productivity efforts.
0
bluebird bio gene therapy lovo-cel for sickle cell disease has $3.1M cost (updated)
https://seekingalpha.com/news/4044803-bluebird-bio-gains-fda-approval-gene-therapy-lovo-cell-sickle-cell-disease?source=feed_sector_healthcare
Dec 08, 2023 - The FDA approves bluebird bio's gene therapy for sickle cell disease, boosting shares by 7%. Read more here.
0
Wells Fargo (WFC) Keeps $750M-$1B of Severance Cost in Q4 2023
https://www.zacks.com/stock/news/2195102/wells-fargo-wfc-keeps-750m-1b-of-severance-cost-in-q4-2023?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2195102
Dec 07, 2023 - Wells Fargo (WFC) puts aside $750 million to less than $1 billion for severance expenses in the fourth quarter of 2023.
0
Strategic Collaborations Aid Genpact (G) Amid Rising Costs
https://www.zacks.com/stock/news/2194885/strategic-collaborations-aid-genpact-g-amid-rising-costs?cid=CS-ZC-FT-analyst_blog|zacks_rank_change-2194885
Dec 07, 2023 - Genpact (G) is growing through its strategic collaborations and shareholder-friendly initiatives, while seasonality and rising costs are worrisome.
0
Loan Growth to Aid Commerce Bancshares (CBSH) Amid Cost Woes
https://www.zacks.com/stock/news/2194869/loan-growth-to-aid-commerce-bancshares-cbsh-amid-cost-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2194869
Dec 07, 2023 - Loan growth will likely continue aiding Commerce Bancshares' (CBSH) revenues. Yet, persistently increasing costs may hurt its bottom line.
0
Donaldson (DCI) Gains on End-Market Strength Amid Cost Woes
https://www.zacks.com/stock/news/2194251/donaldson-dci-gains-on-end-market-strength-amid-cost-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2194251
Dec 06, 2023 - Donaldson (DCI) benefits from strength in the end markets, acquired assets and shareholder-friendly policies while rising expenses remain a concern.
0